Majority of Patients with C Diff Willing to Use Rectally Administered Treatment

Survey results showed patients with a history of live biotherapeutic product therapy preferred rectally administered treatment while patients who had not received live biotherapeutic product therapy would be willing to consider it.

Related Keywords

,Paul Feuerstadt ,Centers For Disease ,Us Centers For Disease ,Yale School Of Medicine ,Yale School Of Medicine Paul Feuerstadt ,Yale School ,Disease Control ,Van Hise ,Rectal Administration ,Recurrent Clostridioides ,Patient Prefer ,Accessed September ,Clotridoides Difficile Infection ,C Diff ,Ccdi ,Fecal Microbiota Transplantation ,Cfmt ,Live Biotherapeutic Product ,Lbp ,